ProtoKinetix AAGP® Dry Eye Therapy Testing Result
Post# of 88
(Total Views: 267)
Posted On: 01/06/2020 9:36:20 AM
ProtoKinetix AAGP® Dry Eye Therapy Testing Results
Marietta, Ohio, January 6, 2020
ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix"
(OTCQB
KTX) announces that ITR Laboratories of Montreal have run multiple tests on eye irritation at maximum concentration of AAGP® and to date have shown no sign of irritation.
About ITR Laboratories
Based on this ProtoKinetix is shipping AAGP® to EyeCRO to commence testing Dry Eye Disease efficacy. This testing will involve topical application of AAGP® and evaluations of its effects on ocular inflammation. EyeCRO is a world recognised, specialised CRO in the field of pre-clinical ocular drug research and development. This program will commence in early January 2020 and is expected to run for 3-4 months.
About EyeCRO
About Dry Eye Disease
Dry Eye Disease is a condition in which a person does not have enough quality tears to lubricate and nourish the eye. Tears are necessary for maintaining the health of the front surface of the eye and for providing clear vision. Dry Eye Disease is a common and often chronic problem, particularly in older adults. This condition currently afflicts more that 30-million Americans (430-million people globally) and can affect as much as 40% of the population for various reasons. The dry eye disease ophthalmic market is very active, with $7.7 billion in revenues and a current growth of 12.5% CAGR.
Marietta, Ohio, January 6, 2020
ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix"
(OTCQBKTX) announces that ITR Laboratories of Montreal have run multiple tests on eye irritation at maximum concentration of AAGP® and to date have shown no sign of irritation. About ITR Laboratories
Based on this ProtoKinetix is shipping AAGP® to EyeCRO to commence testing Dry Eye Disease efficacy. This testing will involve topical application of AAGP® and evaluations of its effects on ocular inflammation. EyeCRO is a world recognised, specialised CRO in the field of pre-clinical ocular drug research and development. This program will commence in early January 2020 and is expected to run for 3-4 months.
About EyeCRO
About Dry Eye Disease
Dry Eye Disease is a condition in which a person does not have enough quality tears to lubricate and nourish the eye. Tears are necessary for maintaining the health of the front surface of the eye and for providing clear vision. Dry Eye Disease is a common and often chronic problem, particularly in older adults. This condition currently afflicts more that 30-million Americans (430-million people globally) and can affect as much as 40% of the population for various reasons. The dry eye disease ophthalmic market is very active, with $7.7 billion in revenues and a current growth of 12.5% CAGR.
(0)
(0)